Elevated expression of IGF1 and IGF2 in CRC as well as co-existence of many metabolic disorders in patients affected by this malignancy (e.g., adiposity, dyslipidemia, hyperinsulinemia, and altered glucose homeostasis) allows to classify the elements of the IGF system as biomarkers of CRC predisposition and prognosis in human [52,53]. This evidence concerns the gene IGF1 and colorectal carcinoma.